Home » Newsletters » BioWorld Science

BioWorld Science

March 2, 2010

View Archived Issues

AstraZeneca discloses novel FGFR inhibitors

Enhanced-sensitivity Trofile assay and HIV V3-loop sequencing comparably predict maraviroc response

FDA approves new labeling of Xylocaine including updated safety information

Prosidion claims new glucose-dependent insulinotropic receptor agonists

Efficacy and safety results of ecallantide treatment for hereditary angioedema attacks

Phase III study supports once-daily dosing of darunavir/ritonavir in HIV-1 infection

Genentech identifies novel MEK inhibitors

Hyperactivity models differentiate SSR-103800 from other antipsychotics

Orchid Research Laboratories presents new PDE4 inhibitor OCI-2987

New voltage-gated sodium channel inhibitors described by Vertex

UCB presents novel PI3K inhibitors

Novartis and Ono submit manufacturing and marketing application in Japan for rivastigmine

COMP grants perifosine positive opinion as orphan medicinal product in MM

Welichem Biotech begins enrollment in phase IIa WBI-1001 trial in psoriasis

FDA accepts for filing VIVUS' Qnexa NDA for obesity

Shionogi provides update on its developments in Q3 of 2009

Ariad's AP-24534 receives orphan drug status for CML

Watson Pharmaceuticals licenses Population Council's novel contraceptive ring

Quark Pharmaceuticals begins dosing in phase I trial of QPI-1007 for NAION

Janssen submits NDA for R-113675 in Japan for AD

Merck KGaA to acquire Millipore

GTC Biotherapeutics provides update on TG-20 MAb

FDA requests Vion conduct phase II trial of Onrigin in AML prior to phase III study

Acorda Therapeutics' Ampyra launched in U.S. and Puerto Rico

Icagen reports phase Ib results on ICA-105665 in pain

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...